All In Biotech

Drug Trial Radar · NCT07602699

Multi-Site Trial of Tirzepatide for Smoking Cessation

A Multi-Site Trial of Tirzepatide for Smoking Cessation

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 5, 2026

Primary completion

Mar 2028

Study completion Sep 2028

Sponsor

Lead sponsor
University of Southern CaliforniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-site clinical trial will generate data on the efficacy of tirzepatide for smoking cessation and associated outcomes (e.g., post-cessation weight gain) in treatment-seeking people who smoke (PWS) with overweight or obesity. A sample of 300 treatment-seeking people who smoke with body mass index of 25 kg/m2 or greater will be recruited from four geographic sites (University of Southern California, Yale University, University of Chicago, and University of Colorado Anschutz Medical Campus) to participate in a parallel-arm, dose-escalating, placebo-controlled trial. Participants will attend weekly clinic visits to receive subcutaneous tirzepatide or placebo over 16 weeks (Visit Weeks 1-16), followed by follow-up visits at Week 17 and Week 27. Medication will be prescribed according to the standard dose titration schedule for the first 16 weeks of treatment (initial dose: 2.5mg/week; final dose: 10mg/week). All participants will also receive nicotine patches.

Conditions

  • Smoking Cessation
  • Smoking Behaviors

Interventions

  • TirzepatideDrug

    Participants will receive tirzepatide (subcutaneous injection) at doses of 2.5mg for Weeks 1-4, 5mg for Weeks 5-8, 7.5mg for Weeks 9-12, and 10mg for Weeks 13-16

  • PlaceboOther

    Participants will receive placebo (saline) injections for Weeks 1-16

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 7-day point prevalence abstinenceTime frame: From baseline through 16 weeks of treatment (final assessment at Week 17 visit) and at 6 months after the target quit date (assessed at Week 27 visit)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Keck School of Medicine, University of Southern California

    Los Angeles, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • University of Chicago Pritzker School of Medicine

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.